Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 210

1.

Dopamine D2-like sites in schizophrenia, but not in Alzheimer's, Huntington's, or control brains, for [3H]benzquinoline.

Seeman P, Guan HC, Nobrega J, Jiwa D, Markstein R, Balk JH, Picetti R, Borrelli E, Van Tol HH.

Synapse. 1997 Feb;25(2):137-46.

PMID:
9021894
2.

Dopamine D4 receptors elevated in schizophrenia.

Seeman P, Guan HC, Van Tol HH.

Nature. 1993 Sep 30;365(6445):441-5.

PMID:
8413587
3.

Human brain D1 and D2 dopamine receptors in schizophrenia, Alzheimer's, Parkinson's, and Huntington's diseases.

Seeman P, Bzowej NH, Guan HC, Bergeron C, Reynolds GP, Bird ED, Riederer P, Jellinger K, Tourtellotte WW.

Neuropsychopharmacology. 1987 Dec;1(1):5-15.

PMID:
2908095
4.

Link between D1 and D2 dopamine receptors is reduced in schizophrenia and Huntington diseased brain.

Seeman P, Niznik HB, Guan HC, Booth G, Ulpian C.

Proc Natl Acad Sci U S A. 1989 Dec;86(24):10156-60.

6.
7.

Low density of dopamine D4 receptors in Parkinson's, schizophrenia, and control brain striata.

Seeman P, Guan HC, Van Tol HH, Niznik HB.

Synapse. 1993 Aug;14(4):247-53.

PMID:
8248849
8.

Striatal dopaminergic markers in dementia with Lewy bodies, Alzheimer's and Parkinson's diseases: rostrocaudal distribution.

Piggott MA, Marshall EF, Thomas N, Lloyd S, Court JA, Jaros E, Burn D, Johnson M, Perry RH, McKeith IG, Ballard C, Perry EK.

Brain. 1999 Aug;122 ( Pt 8):1449-68.

9.

Schizophrenia: elevation of dopamine D4-like sites, using [3H]nemonapride and [125I]epidepride.

Seeman P, Guan HC, Van Tol HH.

Eur J Pharmacol. 1995 Nov 14;286(2):R3-5.

PMID:
8605946
10.

Review the role of dopamine D4 receptors in schizophrenia and antipsychotic action.

Sanyal S, Van Tol HH.

J Psychiatr Res. 1997 Mar-Apr;31(2):219-32. Review.

PMID:
9278187
11.
12.

New insights into dopamine receptors in the central nervous system.

Strange PG.

Neurochem Int. 1993 Mar;22(3):223-36. Review.

PMID:
8095172
13.

Mesolimbic dopamine D3 receptors and use of antipsychotics in patients with schizophrenia. A postmortem study.

Gurevich EV, Bordelon Y, Shapiro RM, Arnold SE, Gur RE, Joyce JN.

Arch Gen Psychiatry. 1997 Mar;54(3):225-32.

PMID:
9075463
14.

Decrease in sigma but no increase in striatal dopamine D4 sites in schizophrenic brains.

Helmeste DM, Tang SW, Bunney WE Jr, Potkin SG, Jones EG.

Eur J Pharmacol. 1996 Oct 31;314(3):R3-5.

PMID:
8957266
15.

Differential labeling of dopamine and sigma sites by [3H]nemonapride and [3H]raclopride in postmortem human brains.

Tang SW, Helmeste DM, Fang H, Li M, Vu R, Bunney W Jr, Potkin S, Jones EG.

Brain Res. 1997 Aug 8;765(1):7-12.

PMID:
9310388
16.

Alterations of striatal dopamine receptor binding in Alzheimer disease are associated with Lewy body pathology and antemortem psychosis.

Sweet RA, Hamilton RL, Healy MT, Wisniewski SR, Henteleff R, Pollock BG, Lewis DA, DeKosky ST.

Arch Neurol. 2001 Mar;58(3):466-72.

PMID:
11255451
17.

Are striatal dopamine D4 receptors increased in schizophrenia?

Reynolds GP, Mason SL.

J Neurochem. 1994 Oct;63(4):1576-7.

PMID:
7931313
18.

Role of dopamine D2-like receptors in cocaine self-administration: studies with D2 receptor mutant mice and novel D2 receptor antagonists.

Caine SB, Negus SS, Mello NK, Patel S, Bristow L, Kulagowski J, Vallone D, Saiardi A, Borrelli E.

J Neurosci. 2002 Apr 1;22(7):2977-88.

19.

Dopamine receptors labelled by PHNO.

Seeman P, Ulpian C, Larsen RD, Anderson PS.

Synapse. 1993 Aug;14(4):254-62.

PMID:
7902615
20.

Effects of hippocampal kainic acid lesions on striatolimbic dopamine D1-, D2-, and D4-like receptors.

Tarazi FI, Campbell A, Baldessarini RJ.

Neuroscience. 1998 Nov;87(1):1-4.

PMID:
9722137
Items per page

Supplemental Content

Write to the Help Desk